Self-administration of Subcutaneous Elranatamab in the Patients' Homes.

Condition:   Multiple Myeloma Intervention:   Drug: Elranatamab Sponsors:   Odense University Hospital;   Pfizer Not yet recruiting

Source: ClinicalTrials.gov - August 29, 2023 Category: Research Source Type: clinical trials